About the Journal | Editorial Board | Instructions to Contributors | Submission & Review | Advertise with Us | Subscribe to E- Alerts
Sitemap | Feedback
Advanced search
Journal of Case Reports
Refractory Thrombotic Thrombocytopenic Purpura
Dawlat Sany1, Wadah Ahmed Osman2, Walaa Abdelmaaboud3, Heba Mohamed Abdelfattah4 
1Departments of Internal Medicine and Nephrology, Kalba Hospital, Sharjah, EHS; 2Department of Internal Medicine, Kalba Hospital, EHS; 3Department of Anesthesia and Critical Care, Khor Fakan Hospital, Sharjah, EHS; 4Department of Pathology, Pure Health Group Company, Sharjah, UAE.
Corresponding Author:
Dr Dawlat Sany
Email: Dawlat.hussein@ehs.gov.ae
Received: 06-NOV-2024 Accepted: 07-JAN-2025 Published Online: 05-MAY-2025
DOI: http://dx.doi.org/10.17659/01.2025.0010
Abstract
Background: Thrombotic thrombocytopenic purpura (TTP) is a rare, life-threatening thrombotic microangiopathy characterized by thrombocytopenia, microangiopathic hemolytic anemia, and severe ADAMTS13 deficiency, often due to inhibitory autoantibodies. If left untreated, the mortality rate can exceed 90%. Case Report: A 44-year-old male presented with fever, confusion, agitation, and pallor. Laboratory evaluation revealed DAT-negative hemolytic anemia, thrombocytopenia, schistocytes on peripheral smear, elevated LDH and creatinine, and neurologic symptoms. His PLASMIC score was high, suggesting severe ADAMTS13 deficiency, later confirmed by a markedly reduced ADAMTS13 activity level (<0.03 IU/mL) and the presence of anti-ADAMTS13 antibodies. The patient was promptly treated with daily therapeutic plasma exchange (TPE) and high-dose methylprednisolone. Due to delayed platelet recovery, rituximab was added, resulting in sustained hematologic improvement. Conclusion: This case highlights the importance of early recognition and prompt initiation of plasma exchange and immunosuppressive therapy in suspected TTP. The addition of rituximab in refractory cases may hasten recovery and reduce the risk of relapse. Timely diagnosis and aggressive treatment are critical to improving outcomes in patients with acquired TTP.
Keywords : Hemolytic Anemia, Plasma Exchange, Rituximab, Steroids, Thrombotic Thrombocytopenic Purpura.
Article Options
FULL TEXT
ABSTRACT
PDF
PRINTER FRIENDLY VERSION
Search PubMed for
Search Google Scholar for
Article Statistics
Bookmark and Share